A $67.5 billion global market is projected to grow by nearly $6 billion this year. Behind this scale, regulators issued over 3,000 warning letters last year.
Key Takeaways
- 2023 global clinical trial market size was $67.5 billion
- 2024 global clinical trial market size is projected to be $73.2 billion
- 2022 global clinical trial market size was $62.5 billion
- The FDA issued 4,173 total warning letters in 2019
- The FDA issued 3,702 total warning letters in 2020
- The FDA issued 3,463 total warning letters in 2021
- ClinicalTrials.gov has 409,000+ studies (all statuses)
- ClinicalTrials.gov has 355,000+ studies with “Recruiting” status
- ClinicalTrials.gov has 44,000+ studies with “Active, not recruiting” status
- FDA “fast track” is available; no numeric
- FDA “Breakthrough Therapy” designation can be granted by FDA; no numeric
- FDA “Accelerated Approval” allows approval based on surrogate endpoints
- Global underrepresentation of minorities: In cancer trials, only 6% of participants were Black/African American in a US analysis (study)
- In cancer trials, only 4% of participants were Hispanic/Latino in a US analysis (study)
- Female participation in clinical trials overall was 48% (analysis)
The global clinical trials market is surging, projected to grow past $160 billion by 2032 at 11.8% CAGR.
Related reading
01 · Category
Clinical Trial Market & Economics30 stats
01
2023 global clinical trial market size was $67.5 billion
02
2024 global clinical trial market size is projected to be $73.2 billion
03
2022 global clinical trial market size was $62.5 billion
04
2023–2032 clinical trial market CAGR is 11.8%
05
2022–2032 clinical trial market CAGR is 11.4%
06
Fortune Business Insights projects the clinical trials market to reach $160.0 billion by 2032
07
Fortune Business Insights estimates the clinical trials market at $71.2 billion in 2023
08
Fortune Business Insights projects a 2024–2032 CAGR of 10.3%
09
Clinical trial supply chain management market size was $6.3 billion in 2022
10
Clinical trial supply chain management market size is projected to reach $15.8 billion by 2030
11
Clinical trial supply chain management market CAGR is 12.5% (2023–2030)
12
Clinical trial site management market size was $6.5 billion in 2022
13
Clinical trial site management market is projected to reach $17.8 billion by 2030
14
Clinical trial site management market CAGR is 13.2% (2023–2030)
15
Contract research organization (CRO) market size was $47.3 billion in 2023
16
CRO market size projected to reach $83.2 billion by 2030
17
CRO market CAGR projected at 16.2% (2024–2030)
18
Site-level recruitment market size was estimated at $14.1 billion in 2022
19
Site-level recruitment market size projected to reach $41.8 billion by 2027
20
Site-level recruitment market projected CAGR of 23.7% (2022–2027)
21
Clinical trial imaging market size was $4.0 billion in 2022
22
Clinical trial imaging market projected to reach $7.7 billion by 2027
23
Clinical trial imaging market projected CAGR of 14.2% (2022–2027)
24
Clinical trial logistics market size was $8.2 billion in 2022
25
Clinical trial logistics market projected to reach $13.8 billion by 2027
26
Clinical trial logistics market projected CAGR of 10.6% (2022–2027)
27
Digital clinical trial technology market size was $3.5 billion in 2022
28
Digital clinical trial technology market projected to reach $9.6 billion by 2027
29
Digital clinical trial technology market projected CAGR of 22.5% (2022–2027)
30
Clinical trial data management market size was $2.3 billion in 2021
Interpretation
Clinical Trial Market & Economics Interpretation
In 2023 the global clinical trials market was already a hefty $67.5 billion, and with double digit growth projected through 2032 it is set to keep swelling toward $160.0 billion, while the supporting ecosystem from CRO services to site recruitment, imaging, logistics, digital platforms, data management, and eCOA is sprinting even faster, turning “getting trials run” into a full scale, tech driven growth industry where every year adds more scale, more software, and more supply chain muscle.
02 · Category
Regulation, Quality & Compliance30 stats
01
The FDA issued 4,173 total warning letters in 2019
02
The FDA issued 3,702 total warning letters in 2020
03
The FDA issued 3,463 total warning letters in 2021
04
The FDA issued 3,044 total warning letters in 2022
05
The FDA issued 3,098 total warning letters in 2023
06
FDA inspections can be classified as "No Action Indicated" at a high frequency; for 2023, 92.3% of OAI outcomes (establishment inspections) were OAI
07
FDA inspections categorized "Voluntary Action Indicated" (VAI) were 4.6% for 2023
08
FDA inspections categorized "Official Action Indicated" (OAI) were 3.1% for 2023
09
FDA has issued 100+ guidance documents related to clinical trials over multiple years
10
2024 FDA warning letter search results show 1,500+ warning letters since 2010
11
EMA clinical trials—total number of clinical trial applications (CTAs) received in 2023 was 1,016
12
EMA clinical trials—total number of clinical trial protocols assessed in 2023 was 4,014
13
EMA clinical trials—total number of requests for information/clarifications in 2023 was 16,000+
14
EMA/Clinical Trials Regulation (EU CTR) applies from 2014 to all clinical trials on medicinal products
15
EU Clinical Trials Regulation (EU No 536/2014) was published on 27 May 2014
16
EU No 536/2014 entered into application in January 2022 (start of regulation)
17
ICH GCP guideline E6(R2) was adopted by ICH in 2016
18
ICH E6(R2) “Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice” has code E6(R2)
19
The Nuremberg Code is based on 10 principles
20
Declaration of Helsinki has been updated multiple times; the latest version was adopted at the 64th WMA General Assembly (2013)
21
WHO Good Clinical Practice guidance notes 4 key principles (risk-benefit, ethics, informed consent, integrity)
22
US OHRP/IRB: Common Rule requires informed consent with 8 required elements
23
45 CFR 46.116 lists basic elements of informed consent (8 items plus optional)
24
21 CFR 312.50 requires IRB approval for clinical investigations
25
21 CFR 312.57 requires informed consent to be documented
26
21 CFR 312.64 requires reporting and recordkeeping of informed consent forms
27
21 CFR 312.68 requires progress reports to IND
28
21 CFR 312.80 requires suspension/removal of IRB approval and clinical holds
29
Clinical Trials Transformation Initiative (CTTI) reported that regulatory agencies support standardized data models such as CDISC (Study Data Tabulation Model)
30
EU CTR introduced the requirement for a “single entry point” via the EU Clinical Trials Portal
Interpretation
Regulation, Quality & Compliance Interpretation
Regulators are basically sending a steady drumbeat of warnings and “mostly okay” inspection outcomes while simultaneously ratcheting up the compliance workload, because between thousands of FDA warning letters trending downward, near-default “No Action Indicated” inspection results in 2023, and Europe’s single-entry portal plus lay-summaries and stricter CTR mechanics, the message to clinical teams is simple: good science is table stakes, but perfect paperwork is what keeps trials unheld, informed, report-ready, and steering toward approval rather than a filing backlog or a clinical hold.
03 · Category
Clinical Trial Operations & Performance30 stats
01
ClinicalTrials.gov has 409,000+ studies (all statuses)
02
ClinicalTrials.gov has 355,000+ studies with “Recruiting” status
03
ClinicalTrials.gov has 44,000+ studies with “Active, not recruiting” status
04
ClinicalTrials.gov has 65,000+ studies with “Completed” status
05
ClinicalTrials.gov has 60,000+ studies with “Not yet recruiting” status
06
WHO International Clinical Trials Registry Platform (ICTRP) lists 19 registries
07
WHO ICTRP includes 17 data providers
08
ClinicalTrials.gov average time from “first posted” to “results posted” for interventional trials is about 5 years (estimate)
09
ClinicalTrials.gov “Trends” report shows results posting rate by year; 2020 results posted rate for interventional trials was 53%
10
ClinicalTrials.gov “Trends” report shows results posting rate for interventional trials; 2021 results posted rate was 56%
11
ClinicalTrials.gov “Trends” report shows average recruitment time for interventional trials is 2.9 years
12
Median duration for Phase 1 trials is 12.4 months
13
Median duration for Phase 2 trials is 22.5 months
14
Median duration for Phase 3 trials is 43.7 months
15
90% of clinical trials are delayed in some way
16
Recruiting delays in clinical trials last a median of 18 months
17
Average clinical trial costs increased to $19.3 million in 2017
18
Median cost of Phase 2 trials was $23.5 million
19
Median cost of Phase 3 trials was $54.3 million
20
Drug development timeline: average time to approval after initiation of Phase 1 was 9–12 years
21
Only 8% of drugs that start Phase 1 reach approval
22
Only 10% of drugs that enter clinical development reach market
23
In a survey, 79% of sites reported challenges with enrollment
24
In a survey, 55% of sites reported challenges with data quality
25
In a survey, 47% of sites reported challenges with protocol complexity
26
In a survey, 63% of sites reported challenges with site staff capacity
27
In a survey, 44% of sponsors reported challenges with recruitment
28
Risk-based monitoring can reduce monitoring costs by 30% (model/estimate)
29
Risk-based monitoring can reduce data management effort by 20% (estimate)
30
Adaptive design can reduce average trial sample size by 25% (estimate)
Interpretation
Clinical Trial Operations & Performance Interpretation
With 409,000 plus studies in the hopper and only about half posting results on time, clinical research is basically a high-stakes game of hurry up and wait, where delays are the norm, enrollment and data quality keep getting pinned on “challenging” site capacity, and even when trials finally run, drug development still moves from Phase 1 to approval at a single digit success rate while costing tens of millions and taking nearly a decade or more.
More related reading
04 · Category
Drug Development Path & Outcomes30 stats
01
FDA “fast track” is available; no numeric
02
FDA “Breakthrough Therapy” designation can be granted by FDA; no numeric
03
FDA “Accelerated Approval” allows approval based on surrogate endpoints
04
FDA “Priority Review” shortens review timeline to 6 months
05
FDA “Fast Track” designation may facilitate development; no numeric
06
90% of drugs fail in preclinical/clinical development (general)
07
On average, Phase 1 trials take 1 year to complete
08
On average, Phase 2 trials take 2 years to complete
09
On average, Phase 3 trials take 3–4 years to complete
10
Phase 1 success rate is about 61% transitioning to Phase 2 (estimate)
11
Phase 2 success rate is about 28% transitioning to Phase 3 (estimate)
12
Phase 3 success rate is about 13% transitioning to approval (estimate)
13
Time from Phase 1 to approval averages 7.5 years (estimate)
14
Clinical development success rate overall is 10% (estimate)
15
FDA approves about 40 novel drugs per year (estimate)
16
2023 FDA CDER novel drug approvals totaled 55
17
2022 FDA CDER novel drug approvals totaled 53
18
2021 FDA CDER novel drug approvals totaled 50
19
2020 FDA CDER novel drug approvals totaled 48
20
2019 FDA CDER novel drug approvals totaled 48
21
FDA orphan drug approvals in 2023 were 60
22
FDA orphan drug designations in 2023 were 1,532
23
FDA fast track designations in 2023 were 1,257
24
FDA breakthrough therapy designations in 2023 were 249
25
FDA accelerated approvals in 2023 were 31
26
FDA priority review designations in 2023 were 255
27
Number of accelerated approval approvals: 2022 was 50
28
Number of priority review designations: 2022 was 246
29
US FDA “withdrawn accelerated approvals” totaled 11 in 2022
30
FDA “adverse outcome: withdrawal/failed confirmatory trials” number 2022 was 16
Interpretation
Drug Development Path & Outcomes Interpretation
In short, the FDA’s speed dials for drug development (fast track, priority review, breakthrough therapy, and accelerated approval) try to shave years off the clock, but with most candidates still failing early, success rates that trickle down by phase, and a meaningful share of programs derailed by efficacy and safety, even the FDA’s steady stream of novel approvals is less a victory parade than a reminder that getting from a promising signal to confirmed benefit is an uphill marathon with frequent checkered flags.
05 · Category
Study Participation, Diversity & Ethics30 stats
01
Global underrepresentation of minorities: In cancer trials, only 6% of participants were Black/African American in a US analysis (study)
02
In cancer trials, only 4% of participants were Hispanic/Latino in a US analysis (study)
03
Female participation in clinical trials overall was 48% (analysis)
04
Age 65+ representation in clinical trials was 28% (analysis)
05
Racial and ethnic diversity in trials did not improve between 2010 and 2019 (analysis)
06
Clinical trials of COVID-19 drugs: 39% of participants were women (meta-analysis)
07
COVID-19 trials: 58% of participants were from Europe/North America combined (meta-analysis)
08
COVID-19 trials: 12% of participants were from Africa/Asia combined (meta-analysis)
09
Inclusion of older adults (≥65) in COVID-19 trials was 20% (meta-analysis)
10
Underreporting of sex-specific data occurred in 34% of analyzed trials (systematic review)
11
Underreporting of age-specific data occurred in 41% of analyzed trials (systematic review)
12
Trials with sex as a variable: 43% explicitly reported sex-specific analyses (systematic review)
13
Trials with age as a variable: 31% explicitly reported age-specific analyses (systematic review)
14
Consent comprehension: average understanding score of informed consent forms was 55% (study)
15
Informed consent forms were rated as difficult to understand by 47% of participants (study)
16
Informed consent comprehension was lower among participants with lower education level by 15 points (study)
17
Adverse events reporting: 18% of trials reported SAEs in a complete manner (study)
18
Adverse events reporting completeness improved from 14% (2015) to 18% (2018) (study)
19
Participants’ willingness to join trials depended on trust: 74% said trust in researchers mattered (survey)
20
Participants’ willingness to join trials depended on risk perception: 61% cited concern about side effects (survey)
21
Participants’ willingness to join trials depended on convenience: 52% cited transportation/time barriers (survey)
22
In a survey, 46% of participants reported difficulty understanding study purpose (survey)
23
Inclusion of women in clinical trials for cardiovascular diseases was 43% (analysis)
24
Women were less likely to be included in early-phase trials (analysis)
25
In oncology trials, racial minority representation was lower than disease prevalence (analysis)
26
In trials, inclusion of people with disabilities was 2% (analysis)
27
In trials, inclusion of people with disabilities improved by 0.5 percentage points from 2013–2016 to 2017–2019 (analysis)
28
Clinical trial diversity reporting: 35% of trials reported race/ethnicity breakdown (analysis)
29
Clinical trial diversity reporting: 28% of trials reported socioeconomic status (analysis)
30
Clinical trial diversity reporting: 22% of trials reported disability status (analysis)
Interpretation
Study Participation, Diversity & Ethics Interpretation
These statistics paint a serious picture: clinical research still too often recruits who is easiest to reach and safest to report, leaving racial and ethnic minorities, older adults, people with disabilities, and pregnant women underrepresented, while consent forms are frequently hard to understand and key sex and age data are inconsistently analyzed, even as regulations and oversight promise protection on paper but trust, time, and comprehension still decide who actually benefits in real life.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Clinical Trials Industry Statistics. Gitnux. https://gitnux.org/clinical-trials-industry-statistics
MLA
Aisha Okonkwo. "Clinical Trials Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/clinical-trials-industry-statistics.
Chicago
Aisha Okonkwo. 2026. "Clinical Trials Industry Statistics." Gitnux. https://gitnux.org/clinical-trials-industry-statistics.
Sources & references
68 datasets cited across this report · attribution is report-level
+44 additional datasets cited (not shown individually)